Clinical Trials

Inclusion Criteria:

• Age 13-18, male or female, any race/ethnicity
• Treating clinician, patient, and family feel that pharmacotherapy is indicated as part of a comprehensive treatment plan.
• Major depressive episode diagnosis or bipolar disorder based on KSADS-PL semi-structured psychiatric interview with a severity criteria-40 or greater on Childhood Depression Rating Scale-Revised (CDRS-R)
• Ability to provide informed consent

Exclusion Criteria:

• Inability to speak English
• Inability or lack of willingness to provide informed consent and assent.
• Axis I diagnoses: Autism Spectrum Disorder, Anorexia Nervosa, Schizophreniform, and Schizophrenia.
• Psychotropic medication change (including dosage) between screening & randomization visits.
• Patients who meet DSM 5 criteria for any significant current substance use disorder other than nicotine, caffeine, or cannabis. Must have at least early, partial or full, remission X 3 months
• Serious suicidal risk and/or in need of immediate hospitalization as judged by the investigator.
• Significant unstable medical condition.
• Anticipated inability to attend scheduled study visits.
• Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol.
• Cytochrome (CYP) & serotonin transporter genomic testing within 5 years.